InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,217.10
(
0.06%
)
US TECH 100
17,652.40
(
0.07%
)
Dow Jones
39,489.53
(
0.26%
)
Brent Oil
83.02
(
-1.11%
)
Bitcoin
61,172.51
(
-2.97%
)
Post# of 6070
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

operating_line

Send PM Follow Ignore
Followers 8
Posts 921
Boards Moderated 0
Alias Born 10/07/2015

operating_line

Re: CVR Investor post# 6023

Thursday, 06/18/2020 12:11:35 AM

Thursday, June 18, 2020 12:11:35 AM

Post# of 6070
best chance is something from CASI first in China

This article suggests $5.4m for Marqibo and Zevalin in 2020. Hard to know what part of that is Marqibo.

"We are reducing our 2020 revenue estimate from $20.8 million to $12.5 million to account for the move away from the ANDA portfolio. We forecast $7.1m in Evomela sales for 2020 and total sales of $12.5 million assuming approval and commercialization for Marqibo and Zevalin."

https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/CASI-A-Change-in-Strategy-article/default.aspx


Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up